Pirarubicin Topoisomerase II inhibitor ab142734 CAS: 72496-41-4

CAS NO: 72496-41-4
Pirarubicin Topoisomerase II inhibitor ab142734
Chemical Name: Pirarubicin
Molecular Formula: C32H37NO12
Formula Weight: 627.64
CAS No.: 72496-41-4
Description Review
Description

Pirarubicin is a chemotherapy drug used in the treatment of various types of cancer, including breast cancer, bladder cancer, and lung cancer. It is an anthracycline antibiotic that works by inhibiting the activity of Topoisomerase II, preventing DNA replication and cell division.

Chemical name: (1S,4S,7S,9S)-4,7-bis(acetyloxy)-9-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy)-6,12,13-trihydroxy-10-methoxy-1,2,3,4,6,9,11,12-octahydro-7,11-methanocycloocta(1,2-b)oxocin-8-one Molecular formula: C32H39NO15 Formula weight: 665.66 g/mol CAS No: 72496-41-4

Top ten keywords from Google and Synonyms:

  1. Topoisomerase II inhibitor
  2. Pirarubicin CAS 72496-41-4
  3. Anti-cancer drug
  4. Anthracycline antibiotic
  5. Chemotherapy
  6. Cancer treatment
  7. Synonyms: Thiarabine; Thiarabin; Timtec-Bb Sbb006408; Tomudex; UNII-GVD16G98HX
  8. Bladder cancer
  9. Lung cancer
  10. Breast cancer

Health benefits of this product: The health benefits of Pirarubicin are centered around its anticancer and antitumor properties. Pirarubicin inhibits the activity of Topoisomerase II - an enzyme that plays a crucial role in the replication and division of DNA in cancer cells. By stopping the replication and division of DNA, Pirarubicin can slow down and prevent the growth of cancerous cells.

Potential effects: Pirarubicin exhibits powerful potential effects on multiple types of cancer. Its properties as a Topoisomerase II inhibitor make it effective in combating several types of solid tumors, such as bladder cancer, breast cancer, and lung cancer. Moreover, this drug can induce apoptosis, promoting cancer cell death and helping to treat and manage cancer in patients.

Product mechanism: Pirarubicin works as a Topoisomerase II inhibitor. Topoisomerases are enzymes that control DNA replication and are essential for the cell to divide. Inhibiting the action of Topoisomerase II with Pirarubicin leads to the accumulation of DNA breaks and prevents further replication and division of the cell. Thus, cancer cells are prevented from growing and multiplying.

Safety: Pirarubicin, like most chemotherapy drugs, might cause adverse side effects such as hair loss and weakened immune system. Patients with liver disease should consult their healthcare provider before taking this drug. Moreover, pregnant and diabetic patients should consult with their doctors before using Pirarubicin.

Side effects: The following are some side effects that have been reported for Pirarubicin:

  1. Nausea and vomiting
  2. Hair loss
  3. Fatigue
  4. Anemia
  5. Infection risk
  6. Low white blood cell count
  7. Neuropathy
  8. Cardiotoxicity
  9. Diarrhea
  10. Mucositis

Dosing information: Pirarubicin dosing can vary based on individual patient circumstances and cancer type, severity, and progression. Your oncologist will determine the optimal dosage, schedule, and duration of treatment based on your overall health and medical history.

Conclusion: Pirarubicin, as a Topoisomerase II inhibitor, is a widely used chemotherapy agent in the treatment of various types of cancer. Its effectiveness in preventing DNA replication and division in cancer cells has made it an essential treatment method, although it might cause some side effects. Over the years, extensive clinical trials have been conducted, and Pirarubicin has shown subduing results in the treatment of solid tumors such as bladder, lung, and breast cancer. However, the drug should be used with caution under the appropriate medical supervision, as it could carry adverse effects. Nevertheless, Pirarubicin remains a potent chemotherapy agent used in the fight against cancer.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us